On Monday January 7, 2019, KEI submitted joint comments on behalf of Health GAP, Social Security Works, the Union for Affordable Cancer Treatment, and Professor Brook Baker of Northeastern University to the Federal Register notice (83 FR 65694) for the”Prospective… Continue Reading
KEI Comments on Medicare Programs: International Pricing Index Model for Medicare Part B Drugs (CMS-5528-ANPRM) Knowledge Ecology International (KEI) is a non-profit organization that focuses on the management of knowledge goods, including new drugs, vaccines and other medical therapies. Much… Continue Reading
The following are comments by KEI, UACT, Social Security Works, HealthGap, Public Citizen, Dr. Ophira Ginsbug and James Love on an NIH proposed exclusive license for patents on a CAR T technology for “Treatment of FMS-Like Tyrosine Kinase 3 (FLT3)… Continue Reading
On Monday, 3 December 2018, Knowledge Ecology International (KEI) delivered this opening statement at WIPO’s 29th Session of the Standing Committee on the Law of Patents (SCP). Thank you Chair. KEI welcomes the conclusions of SCP 28 which call upon… Continue Reading
In a recent Federal Register notice, the National Institutes of Health (NIH) has announced its intent to grant an exclusive patent license on chimeric antigen receptor (CAR) therapies for the treatment of certain cancers to ElevateBio, a company located in… Continue Reading
DATE: Thursday, 6 December 2018 TIME: 1:30 PM to 3 PM VENUE: Room B CONVENER: Knowledge Ecology International (KEI) Knowledge Ecology International (KEI) cordially invites you to attend our side event during negotiations of the 29th Session of the Standing… Continue Reading
This October 11, 2017 email, from Catherine Robinson of Pfizer to Daniel Watson and John Meile of USTR, asks USTR to block a competitor from a tender to sell a drug. USTR provides one email and redacts details including the… Continue Reading
The following PDF file includes several email exchanges between Pfizer and USTR regarding Colombia’s accession to the Organisation for Economic Co-operation and Development (OECD). Pfizer proposed several conditions it wanted Colombia to agree to before the US would withdraw objections… Continue Reading
KEI has received Pfizer and USTR emails and a Pfizer briefing memo to USTR from September 2017, asking the USTR to block a Malaysia Requirement to disclose drug prices. The documents were obtained under a Freedom of Information request to… Continue Reading
The attached document is a 78 page PDF file obtained from USTR under the Freedom of Information Act (copy here), regarding communications between Gilead and USTR, over Malaysia’s decision to grant a compulsory license on patents for HCV treatments. This… Continue Reading